Literature DB >> 24126582

Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates.

Mariana Castanheira1, Leah N Woosley, Shawn A Messer, Daniel J Diekema, Ronald N Jones, Michael A Pfaller.   

Abstract

Among 119 echinocandin non-wild-type (non-WT) Candida glabrata strains from two global surveys, mutations in fks hot spots (HSs) were detected in 28 (from 7 countries and 8 U.S. states): 24 strains (85.7%) had non-WT MICs for micafungin, 22 (78.6%) for anidulafungin, and 25 (89.3%) for caspofungin. The most common FKS substitutions among non-WT strains were at positions F659 (n = 7) and S663 (n = 7). Three isolates displaying WT MIC results had F625Y, L630I, and D632Y substitutions or non-HS mutations. Mutations that have been reported to decrease the echinocandin binding to the 1,3-β-d-glucan synthase were categorized as resistant by applying the new CLSI breakpoint criteria for all three echinocandins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24126582      PMCID: PMC3910756          DOI: 10.1128/AAC.01674-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST).

Authors:  Maiken C Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William Hope
Journal:  Clin Microbiol Infect       Date:  2012-05-08       Impact factor: 8.067

Review 2.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

3.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

Authors:  J Turnidge; G Kahlmeter; G Kronvall
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

4.  Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility.

Authors:  Kelley R Healey; Santosh K Katiyar; Mariana Castanheira; Michael A Pfaller; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

5.  Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida.

Authors:  Michael A Pfaller; Mariana Castanheira; Daniel J Diekema; Shawn A Messer; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2011-09-07       Impact factor: 5.948

6.  Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots.

Authors:  Maiken Cavling Arendrup; Juan-Luis Rodriguez-Tudela; Steven Park; Guillermo Garcia-Effron; Guillaume Delmas; Manuel Cuenca-Estrella; Alicia Gomez-Lopez; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

7.  Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.

Authors:  Maiken Cavling Arendrup; David S Perlin; Rasmus Hare Jensen; Susan Julie Howard; Joanne Goodwin; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

8.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

9.  Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida.

Authors:  Luis Ostrosky-Zeichner
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

10.  Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.

Authors:  Alexander Lepak; Mariana Castanheira; Daniel Diekema; Michael Pfaller; David Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

View more
  30 in total

1.  Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

2.  Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility.

Authors:  M Martí-Carrizosa; F Sánchez-Reus; F March; E Cantón; P Coll
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

3.  Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for FKS-Associated Echinocandin Resistance in Candida glabrata Septic Arthritis and Osteomyelitis.

Authors:  William F Wright; Nika Bejou; Ryan K Shields; Kieren Marr; Todd P McCarty; Peter G Pappas
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 4.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

5.  Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC.

Authors:  Takeshi Saraya; Koichi Tanabe; Koji Araki; Shota Yonetani; Hiroshi Makino; Takayasu Watanabe; Naoki Tsujimoto; Saori Takata; Daisuke Kurai; Haruyuki Ishii; Yoshitsugu Miyazaki; Hajime Takizawa; Hajime Goto
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

6.  Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar.

Authors:  Saad J Taj-Aldeen; Husam Salah; Winder B Perez; Muna Almaslamani; Mary Motyl; Atqah AbdulWahab; Kelley R Healey; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

7.  Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Richard Cumbie; Eileen Driscoll; A William Pasculle; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

8.  Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Katyna Borroto-Esoda; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

9.  Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.

Authors:  Mariana Castanheira; Lalitagauri M Deshpande; Andrew P Davis; Paul R Rhomberg; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

10.  Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.

Authors:  A Espinel-Ingroff; M Alvarez-Fernandez; E Cantón; P L Carver; S C-A Chen; G Eschenauer; D L Getsinger; G M Gonzalez; N P Govender; A Grancini; K E Hanson; S E Kidd; K Klinker; C J Kubin; J V Kus; S R Lockhart; J Meletiadis; A J Morris; T Pelaez; G Quindós; M Rodriguez-Iglesias; F Sánchez-Reus; S Shoham; N L Wengenack; N Borrell Solé; J Echeverria; J Esperalba; E Gómez-G de la Pedrosa; I García García; M J Linares; F Marco; P Merino; J Pemán; L Pérez Del Molino; E Roselló Mayans; C Rubio Calvo; M Ruiz Pérez de Pipaon; G Yagüe; G Garcia-Effron; J Guinea; D S Perlin; M Sanguinetti; R Shields; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.